RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy

被引:110
作者
Coughlin, CM
Vance, BA
Grupp, SA
Vonderheide, RH
机构
[1] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
关键词
D O I
10.1182/blood-2003-07-2379
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vaccination with antigen-presenting cells (APCs) engineered to mimic mechanisms of immune stimulation represents a promising approach for cancer immunotherapy. Dendritic cell vaccines have entered phase 3 testing in adult malignancies, but such vaccines in children have been limited. We demonstrate that CD40-activated B cells (CD40-B) transfected with RNA may serve as an alternative vaccine that can be generated from small. blood volumes regardless of patient age. CD40-B from pediatric patients are efficient APCs and can be loaded with RNA as an antigenic payload, permitting simultaneous targeting of multiple antigenic epitopes without the necessity of HLA matching. For viral and tumor antigens, CD40-B/ RNA technology induced cytotoxic T lymphocytes (CTLs) from adults and children, which could be identified with peptide/major histocompatibility complex (MHC) tetramers. These CTLs secreted interferon-gamma (IFN-gamma) and killed targets in an MHC-restricted fashion. For pooled neuroblastoma RNA and autologous neuroblastoma RNA, CTLs that lysed neuroblastoma cell lines, including CTLs specific against the widely expressed tumor-antigen survivin, were generated. These findings support a novel platform for tumor-specific vaccine or adoptive immunotherapies in pediatric malignancies. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2046 / 2054
页数:9
相关论文
共 55 条
[11]  
BUHLMANN JE, 1995, IMMUNITY, V2, P645
[12]   Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Histopathologic features - A report from the Children's Cancer Group [J].
Cooper, R ;
Khakoo, Y ;
Matthay, KK ;
Lukens, JN ;
Seeger, RC ;
Stram, DO ;
Gerbing, RB ;
Nakagawa, A ;
Shimada, H .
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (06) :623-629
[13]   Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study [J].
Dagher, R ;
Long, LM ;
Read, EJ ;
Leitman, SF ;
Carter, CS ;
Tsokos, M ;
Goletz, TJ ;
Avila, N ;
Berzofsky, JA ;
Helman, LJ ;
Mackall, CL .
MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 38 (03) :158-164
[14]   Resting B lymphocytes as APC for naive T lymphocytes: Dependence on CD40 ligand/CD40 [J].
Evans, DE ;
Munks, MW ;
Purkerson, JM ;
Parker, DC .
JOURNAL OF IMMUNOLOGY, 2000, 164 (02) :688-697
[15]   CD48-CD40 ligand interactions stimulate B cell antigen processing [J].
Faassen, AE ;
Dalke, DP ;
Berton, MT ;
Warren, WD ;
Pierce, SK .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (12) :3249-3255
[16]   Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy [J].
Fong, L ;
Hou, YF ;
Rivas, A ;
Benike, C ;
Yuen, A ;
Fisher, GA ;
Davis, MM ;
Engleman, EG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8809-8814
[17]   B-CELLS TURN OFF VIRGIN BUT NOT MEMORY T-CELLS [J].
FUCHS, EJ ;
MATZINGER, P .
SCIENCE, 1992, 258 (5085) :1156-1159
[18]  
Geiger JD, 2001, CANCER RES, V61, P8513
[19]   Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors [J].
Heiser, A ;
Coleman, D ;
Dannull, J ;
Yancey, D ;
Maurice, MA ;
Lallas, CD ;
Dahm, P ;
Niedzwiecki, D ;
Gilboa, E ;
Vieweg, J .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) :409-417
[20]   Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA [J].
Heiser, A ;
Maurice, MA ;
Yancey, DR ;
Wu, NZ ;
Dahm, P ;
Pruitt, SK ;
Boczkowski, D ;
Nair, SK ;
Ballo, MS ;
Gilboa, E ;
Vieweg, J .
JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :2953-2960